Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.
about
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Durable treatment-free remissi ...... ate of the ENESTfreedom study.
@en
Durable treatment-free remissi ...... ate of the ENESTfreedom study.
@nl
type
label
Durable treatment-free remissi ...... ate of the ENESTfreedom study.
@en
Durable treatment-free remissi ...... ate of the ENESTfreedom study.
@nl
prefLabel
Durable treatment-free remissi ...... ate of the ENESTfreedom study.
@en
Durable treatment-free remissi ...... ate of the ENESTfreedom study.
@nl
P2093
P2860
P50
P1476
Durable treatment-free remissi ...... ate of the ENESTfreedom study.
@en
P2093
Andrzej Hellmann
Eibhlin Conneally
Francis J Giles
Giuseppe Saglio
Jerald P Radich
Jesper Stentoft
Nancy Krunic
Philipp D le Coutre
Prashanth Gopalakrishna
Susanne Saussele
P2860
P2888
P304
P356
10.1007/S00432-018-2604-X
P577
2018-02-22T00:00:00Z